André B. P. Kuilenburg

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.

Nicole Back, Monique Nijhuis, Wilco Keulen et al. · The EMBO Journal · 1996 · 412 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.

André B. P. Kuilenburg, Janet Haasjes, Dick J. Richel et al. · PubMed · 2000 · 360 citations

Life Sciences, Biochemistry, Pharmacology +14

Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.

André B. P. Kuilenburg, E.W. Muller, Janet Haasjes et al. · PubMed · 2001 · 255 citations

Life Sciences, Genetics, Molecular Genetics +17

Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.

Martin Kristian Raida, Wolfgang Schwabe, Peter Häusler et al. · PubMed · 2001 · 232 citations

Life Sciences, Genetics, Oncology +17